Phone: 1.510.856.5600|info@anthera.com

Press Releases

 
Press Releases
  Date Title and Summary View
May 15, 2017
Four-week non-inferiority, Coefficient of Fat Absorption (CFA) primary endpoint comparing Sollpura to Pancreaze in patients with exocrine pancreatic insufficiency due to cystic fibrosisStudy design leverages input from the US FDA and CF CommunityTarget enrollment of 150 patients 7 years of age and olderTop line data expected end of 2017 or early 20...
May 10, 2017
RESULT, pivotal Phase 3 Study of Sollpura, is expected to screen the first patient in MayFavorable trends on weight, height, and body mass index ("BMI") from the Extension Period of the SOLUTION Study of SollpuraCompletion of dosing in the Phase 2 BRIGHT-SC Study of blisbimod in patients with IgA NephropathyClosing of initial $15 million public off...
Apr 28, 2017
HAYWARD, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) announced today that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-8 reverse stock split of its common stock, effective as of April 28, 2017 at 5:00 p.m. Eastern Time.  A Certificate ...
Apr 10, 2017
HAYWARD, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals. (Nasdaq:ANTH) today announced the completion of dosing in the randomized, double-blind, placebo controlled, Phase 2 BRIGHT-SC study of blisibimod in patients with IgA nephropathy (IgAN).  After Week 24, patients were given the opportunity to continue blinded treatment fo...
Mar 29, 2017
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the findings from the Extension Period of the Phase 3 SOLUTION, non-inferior...
Mar 14, 2017
HAYWARD, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the "Company") today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price of $0.50 per share and two tranches of warrants to purchase an aggregate of 60,000,000 shares of its common stock. The gr...
Mar 13, 2017
HAYWARD, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the "Company") today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.  In addition, the Company intends to grant the underwriters a 30-day op...
Feb 27, 2017
SOLUTION study with Sollpura™ missed non-inferiority endpoint by 1%, prompting new phase 3 studyData Monitoring Committee issued recommendation to continue SIMPLICITY study with Sollpura™Blisibimod for the treatment of IgA Nephropathy demonstrated positive trends at week 48Blisibimod for the treatment of systemic lupus terminatedCraig T...
Dec 27, 2016
Sollpura narrowly missed the primary endpoint for change in the Coefficient of Fat Absorption (CFA) non-inferiority marginSollpura demonstrated non-inferiority in the per protocol CFA analysisSollpura demonstrated non-inferiority in Coefficient of Nitrogen Absorption (CNA) analysesAnthera will initiate a new study to demonstrate the efficacy of Sol...
Dec 13, 2016
HAYWARD, Calif., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data Monitoring Committee (DMC) completed its pre-planned safety review of the SIMPLICITY clinical study of Sollpura supplied as a powder for oral solution in an initial cohort of cystic fibrosis patients  seven years of age and...
Page:
1
... NextLast
= add release to Briefcase
Print Friendly